EOM Pharmaceutical (OTCMKTS:IMUC) vs. VYNE Therapeutics (NASDAQ:VYNE) Critical Survey

EOM Pharmaceutical (OTCMKTS:IMUC) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Valuation and Earnings

This table compares EOM Pharmaceutical and VYNE Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EOM Pharmaceutical	N/A	N/A	-$1.89 million	N/A	N/A
VYNE Therapeutics	$500,000.00	18.85	-$39.83 million	($0.90)	-0.41

EOM Pharmaceutical has higher earnings, but lower revenue than VYNE Therapeutics.

Analyst Ratings

This is a breakdown of current ratings for EOM Pharmaceutical and VYNE Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EOM Pharmaceutical	0	0	0	0	0.00
VYNE Therapeutics	1	3	0	0	1.75

VYNE Therapeutics has a consensus price target of $6.25, indicating a potential upside of 1,589.19%. Given VYNE Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe VYNE Therapeutics is more favorable than EOM Pharmaceutical.

Profitability

This table compares EOM Pharmaceutical and VYNE Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EOM Pharmaceutical	N/A	N/A	N/A
VYNE Therapeutics	-8,097.69%	-77.57%	-63.09%

Institutional & Insider Ownership

83.8% of VYNE Therapeutics shares are owned by institutional investors. 3.3% of EOM Pharmaceutical shares are owned by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

EOM Pharmaceutical has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.

Summary

VYNE Therapeutics beats EOM Pharmaceutical on 6 of the 10 factors compared between the two stocks.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.